ArticleThe Journal of pathology2011
The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
Article in The Journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [Molecular diagnosis & therapy · 2025Review
- Neutrophil diversity and function in health and disease.Signal transduction and targeted therapy · 2024Review
- Integrated multiplex network based approach reveled CC and CXC chemokines associated key biomarkers in colon adenocarcinoma patients.American journal of cancer research · 2023Article
- Investigating novel biomarkers in uterine corpus endometrial carcinoma: in silico analysis and clinical specimens validation via RT-qPCR and immunohistochemistry.American journal of cancer research · 2023Article
- CXCR4-targeted theranostics in oncology.European journal of nuclear medicine and molecular imaging · 2022Review
- Current Status ofDiagnostics (Basel, Switzerland) · 2022Review
- CXCR4 engagement triggers CD47 internalization and antitumor immunization in a mouse model of mesothelioma.EMBO molecular medicine · 2021Article
- The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration.Frontiers in immunology · 2020Review
- The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy.Frontiers in oncology · 2019Review
- Targeting CXCR4 with [Oncotarget · 2017Article
- Targeting YAP in malignant pleural mesothelioma.Journal of cellular and molecular medicine · 2017Article
- Low-dose photon irradiation induces invasiveness through the SDF-1α/CXCR4 pathway in malignant mesothelioma cells.Oncotarget · 2017Article
- DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.International journal of oncology · 2017Article
- Inhibition of CXCR4 and CXCR7 for reduction of cell proliferation and invasion in human endometrial cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Radiation-induced pulmonary injury accelerated pulmonary metastasis in a mouse model of breast cancer.Oncology letters · 2015Article
- Reactive oxygen species a double-edged sword for mesothelioma.Oncotarget · 2015Review
- Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.Oncotarget · 2015Article
- CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.Journal of experimental & clinical cancer research : CR · 2014Article
- Upregulation of chemokine receptor CCR10 is essential for glioma proliferation, invasion and patient survival.Oncotarget · 2014Article
- Differential expression of SDF-1 isoforms in bladder cancer.The Journal of urology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
The chemokine CXCL12 and its receptors, CXCR4 and CXCR7, are involved in tumour progression, metastasis, and survival. We investigated the expression of CXCR4, CXCL12, and CXCR7 in malignant pleural mesothelioma to determine if they are possible biomarkers and potential therapeutic targets. Forty-one mesothelioma tumour tissues, ten normal human pleural tissues, and two mesothelioma cell lines were stained with anti-CXCR4, anti-CXCL12, anti-CXCR7, and anti-p-Akt antibodies. RT-PCR was performed to determine the expression of CXCR4, CXCL12, and CXCR7 in six human mesothelioma cell lines (H28, 211H, H2052, ms-1, H290, and H513) and one human normal mesothelial cell line, LP9. These seven cell lines were also stained with anti-CXCR7. We found that CXCR4 and CXCL12 were expressed in 97.6% and 78.0% mesothelioma tissue samples, concurrently with strong expression of p-Akt (R(2) = 0.739 and 0.620, respectively). In addition, CXCR7 expression was weaker than CXCR4 expression in mesothelioma tissues. Furthermore, RT-PCR showed that CXCR4 and CXCL12 were overexpressed in 5/6 mesothelioma cell lines (211H, H2052, ms-1, H290, and H513), whereas CXCR7 was overexpressed in only 2/6 (H513 and H2052). Moreover, we found that the CXCR4 antagonist AMD3100 inhibited the growth of all five mesothelioma cell lines that overexpress CXCR4 and CXCL12. Our results suggest that the Akt-mTOR pathway is involved during the interruption of the CXCL12/CXCR4 axis in these five mesothelioma cell lines. In conclusion, CXCR4 and CXCL12 are highly expressed in most mesothelioma cell lines and tumour tissues, suggesting that CXCR4 and CXCL12 may be used as biomarkers for patients with mesothelioma. The CXCL12-CXCR4 interaction may be a potential therapeutic target for mesothelioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.